Nirsevimab Effectiveness Against Intensive Care Unit Admission for Respiratory Syncytial Virus in Infants - 24 States, December 2024-April 2025.
Saved in:
| Title: | Nirsevimab Effectiveness Against Intensive Care Unit Admission for Respiratory Syncytial Virus in Infants - 24 States, December 2024-April 2025. |
|---|---|
| Authors: | Zambrano LD, Simeone RM, Newhams MM, Payne AB, Halasa NB, Orzel-Lockwood AO, Calixte JM, Kamidani S, Crandall H, Cameron MA, Schuster JE, Maddux AB, Chiotos K, Irby K, Shein SL, Staat MA, Martin LM, Bhumbra SS, Nofziger RA, Chauhan JC, Zerr DM, Gertz SJ, Guzman-Cottrill JA, Kong M, Hume JR, Coates BM, Michelson KN, Levy ER, Bradford TT, Schwartz SP, Walker TC, Stockwell MS, Biggs A, Hogan AH, Lindsey K, Campbell AP, Randolph AG |
| Corporate Authors: | Overcoming RSV Investigators |
| Source: | MMWR. Morbidity and mortality weekly report [MMWR Morb Mortal Wkly Rep] 2025 Nov 20; Vol. 74 (37), pp. 580-588. Date of Electronic Publication: 2025 Nov 20. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: U.S. Centers for Disease Control Country of Publication: United States NLM ID: 7802429 Publication Model: Electronic Cited Medium: Internet ISSN: 1545-861X (Electronic) Linking ISSN: 01492195 NLM ISO Abbreviation: MMWR Morb Mortal Wkly Rep Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
